Association between Circulatory and Plaque Resistin Levels with Carotid Plaque Instability and Ischemic Stroke Events
ses of ischemic stroke. The risk of ischemic stroke increases with the degree of carotid stenosis and plaque vulnerability. The aim of this study was to investigate the association of circulating and plaque resistin levels with plaque vulnerability and ischemic stroke events in patients with moderate- to high-grade carotid artery stenosis.
Methods: 40 patients with ischemic stroke events and
38 neurologically asymptomatic patients scheduled for carotid endarterectomy were recruited for this study. Fasting blood samples for laboratory analysis were collected preoperatively and serum resistin levels were measured by enzyme-linked immunosorbent assays. Carotid endarterectomy specimens were analyzed according to the gold-standard procedure of histological classification. Plaque resistin expression was determined by standard immunohistochemical procedure.
Results: Serum resistin levels and resistin plaque expression were found to be significantly higher in subjects with unstable carotid plaque (P < .001) while significantly higher serum resistin levels were also present in patients with ischemic stroke events (P < .001). In univariate stepwise logistic regression analysis, higher serum resistin levels were significantly associated with plaque instability (OR 2.223, 95% CI 1.488-3.320, P < .0001) and ischemic stroke events (OR 1.237, 95% CI 1.079-1.420, P = .002). There was also a significant association between higher serum and plaque resistin expression (OR 1.663, 95% CI1.332-2.077, P < .0001). These associations remained significant in all models of multivariate logistic regression analysis. High serum and plaque resistin levels were also significantly associated with specific histological features of plaque instability.
Conclusion: The results suggests that serum resistin levels may be used as a potential biomarker of plaque vulnerability and ischemic stroke events in patients with moderate- to high-grade carotid artery stenosis and highlight the possible relationship that plaque resistin expression has with histological features of plaque vulnerability.
Calabro P, Samudio I, Willerson JT, Yeh ET. 2004. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110:3335-40.
Cho Y, Lee SE, Lee HC, et al. 2011. Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 57:99-109.
Efstathiou SP, Tsiakou AG, Tsioulos DI, et al. 2007. Prognostic significance of serum resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 378:78-85.
Faxon DP, Fuster V, Libby P, et al. 2004. for the American Heart Association. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 109:2617-25.
Flaherty ML, Kissela B, Khoury JC, et al. 2013. Carotid artery stenosis as a cause of stroke. Neuroepidemiology 40:36-41.
Gasbarrino K, Mantzoros C, Gorgui J, et al. 2016. Circulating chemerin is associated with carotid plaque instability, whereas resistin is related to cerebrovascular symptomatology. Arterioscler Thromb Vasc Biol 36:1670-8.
Grant EG, Benson CB, Moneta GL, et al. 2003. Carotid artery stenosis: gray-scale and Doppler US diagnosis: Society of Radiologists in Ultrasound Consensus Conference. Radiology 229:340-6.
Jung HS, Park KH, Cho YM, et al. 2006. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69:76-85.
Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA. 2006. High serum resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 91:2755-60.
Lovett JK, Gallagher PJ, Rothwell PM. 2004. Reproducibility of histological assessment of carotid plaque: Implications for studies of carotid imaging. Cerebrovasc Dis 18:117-23.
Lovett JK, Gallagher PJ, Hands LJ, Walton J, Rothwell PM. 2004. Histological correlates of carotid plaque surface morphology on lumen contrast imaging. Circulation 110:2190-7.
Mukherjee D, Yadav JS. 2000. Carotid and cerebrovascular disease. Cardiol Rev 8:322-32.
Naghavi M, Libby P, Falk E, et al. 2003. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108:1664-72.
Nighoghossian N, Derex L, Douek P. 2005. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 36:2764-72.
Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. 2013. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 227:216-21.
Park HK, Ahima RS. 2013. Resistin in rodents and humans. Diabetes Metab J 37:404-14.
Perovic E, Mrdjen A, Harapin M, Tesija KA, Simundic AM. 2017. Diagnostic and prognostic role of resistin and copeptin in acute ischemic stroke. Top Stroke Rehabil 24:614-18.
Prugger C, Luc G, Haas B, Arveiler D, et al. 2012. PRIME Study Group Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol 71:478-86.
Prugger C, Luc G, Haas B, et al. 2013. PRIME Study Group. Multiple biomarkers for the prediction of ischemic stroke: the PRIME study. Arterioscler Thromb Vasc Biol 33:659-66.
Robati RM, Partovi-Kia M, Haghighatkhah HR, Younespour S, Abdollahimajd F. 2014. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: is psoriasis associated with atherosclerosis? J Am Acad Dermatol 71:642-8.
Rubio-Guerra AF, Cabrera-Miranda LJ, Vargas-Robles H, Maceda-Serrano A, Lozano-Nuevo JJ, Escalante-Acosta BA. 2013. Correlation between levels of circulating adipokines and adiponectin/resistin index with carotid intima-media thickness in hypertensive type 2 diabetic patients. Cardiology 125:150-3.
Shin HJ, Park S, Yoon SJ, et al. 2008. Association between serum resistin and carotid intima media thickness in hypertension patients. Int J Cardiol 125:79-84.
Stary HC. 2000. Natural history and histological classification of atherosclerotic lesions: An update. Arterioscler Thromb Vasc Biol 20:1177-8.
Verma S, Li SH, Wang CH, et al. 2003. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108:736-40.
von Reutern GM1, Goertler MW, Bornstein NM, et al. 2012. Neurosonology Research Group of the World Federation of Neurology. Grading carotid stenosis using ultrasonic methods. Stroke 43:916-21.
Wang H, Wang YT, Fan L, et al. 2014. Resistin might not be a risk factor for carotid artery atherosclerosis in elderly Chinese males. J Geriatr Cardiol 11:222-8.
Xu W, Yu L, Zhou W, Luo M. 2006. Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun 351:376-82.
Yang W, Li Y, Wang JY, Han R, Wang L. 2018. Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study. Cardiovasc Diabetol 17:75.
Yazıcı D, Yavuz D, Öğünç AV, et al. 2012. Serum adipokine levels in type 1 diabetic patients: association with carotid intima media thickness. Metab Syndr Relat Disord 10:26-31.
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).